In late September 2026, the British National Health Service introduced a groundbreaking genomic test that can identify the type of brain tumor in under two hours, a dramatic improvement from the previous six to eight weeks, according to NHS England. This test, developed in Nottingham, reads the tumor's DNA directly rather than relying on traditional microscopic examination, a method that can be both time-consuming and less precise. The test is set to enter trials at five specialized hospitals before being rolled out more widely across the country. Previously, after a biopsy, a neuropathologist would examine the tissue under a microscope, followed by staining and further analysis, a process that could take several weeks. The new test uses a technology called nanopore DNA sequencing, which reads the genetic code by threading the DNA molecule through a tiny pore, one letter at a time. The sequencing device, roughly the size of a thumb, can be placed directly on the operating room table. In a matter of minutes, the device identifies genetic mutations and anomalies specific to each type of tumor. Unlike the microscope, which only considers the shape of the cells, this genetic test provides a more accurate classification based on the tumor's molecular makeup. This aligns with the current medical approach, which increasingly defines brain tumors by their genetic characteristics as much as by their appearance. Dr. Simon Paine likened the old method to reading the future in a crystal ball, emphasizing the imprecision and uncertainty of traditional diagnosis. The speed of this new test can significantly impact patient care. In the best cases, results are available within twenty minutes, while the surgeon is still operating. For example, a 55-year-old man in Nottingham who was undergoing emergency surgery for a glioblastoma—a highly aggressive brain tumor—received his diagnosis before the operation concluded. This immediate information allows doctors to make critical decisions about treatment, including the choice of medications and the extent of tumor removal. A faster diagnosis also allows for earlier initiation of radiotherapy or chemotherapy, potentially saving crucial weeks in the treatment timeline. It also provides earlier access to clinical trials, which are especially valuable for aggressive cancers. In the UK, nearly 13,000 people are diagnosed with primary brain tumors each year. The device was developed through a collaboration between the University of Nottingham and the city's university hospital. Initial trials will take place in Nottingham, Birmingham, Newcastle, and at Great Ormond Street and King's College hospitals in London, with additional cities like Bristol, Oxford, Leeds, and Manchester expected to join in the future. The importance of this advancement extends beyond improving patient comfort. Brain tumors are the leading cause of cancer-related deaths among people under forty. Before widespread use, the test must prove its reliability on a large scale. By enabling almost immediate diagnosis, British hospitals aim to gain crucial time between surgery and the start of treatment, which could significantly improve patient outcomes.